GH Research (GHRS)

Executive Summary

GH Research is a clinical-stage biopharmaceutical company focused on developing mebufotenin-based therapies for psychiatric disorders with high unmet need, including treatment-resistant depression (TRD), bipolar II disorder, and postpartum depression. The company's proprietary platform delivers ultra-rapid and durable remission through innovative formulations and individualized dosing. GH Research has completed several Phase 1 and Phase 2 trials, with the most notable being a Phase 2b trial in TRD (NCT05800860) that completed in March 2025. Despite some terminated Phase 2 trials in bipolar II and postpartum depression, the company is advancing its lead program, GH001, into Phase 3 development for TRD. With a strong scientific rationale, a novel mechanism targeting the 5-HT2A receptor, and a growing body of clinical data, GH Research is positioned to address the significant need for fast-acting antidepressants. The company's valuation of ~$1.57B reflects investor optimism, but execution risks remain given the early stage.

Upcoming Catalysts (preview)

• H2 2026Phase 2b TRD Top-Line Data Publication or Presentation80% success
• H1 2027Initiation of Phase 3 Program for GH001 in TRD70% success
• 2026-2027Potential Partnership or Collaboration for Non-TRD Indications50% success